Suppr超能文献

西班牙接受肝移植评估的肝硬化患者中乙型和甲型肝炎病毒标志物的流行情况及疫苗接种指征

Prevalence of hepatitis B and A virus markers and vaccination indication in cirrhotic patients evaluated for liver transplantation in Spain.

作者信息

Gutiérrez Domingo I, Pascasio Acevedo J M, Alcalde Vargas A, Ramos Cuadra A, Ferrer Ríos M T, Sousa Martín J M, Sayago Mota M, Giráldez Gallego A, Suárez Artacho G

机构信息

Department of Digestive Diseases, Virgen del Rocío University Hospital, Seville, Spain.

出版信息

Transplant Proc. 2012 Jul-Aug;44(6):1502-4. doi: 10.1016/j.transproceed.2012.05.020.

Abstract

In the absence of immunity, vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for patients with chronic liver disease and those evaluated for liver transplantation (OLT) HAV and HBV infections after OLT which are frequent in this setting, are associated with a worse prognosis. The aim of this study was to estimate the need for vaccination against HBV and HAV among cirrhotic patients who were candidates for OLT and associations with gender, age, and etiologic factors. HBV and HAV serological markers HBsAg, anti-HBc, antiHBs, immunoglobulin G (IgG)-anti-HAV were investigated among 568 patients, including 75% men. The overall mean age was 53.6 ± 8.9 years range 17-69, and 20% were diabetic. This etiologies were alcohol (68%), hepatitis C virus (35%) or other causes (10.4%). Child-Pugh classes were: A (26%), B (44%), and C (30%). In contrast with 359 patients (63.2%) who had negative HBV markers, 209 (36.8%) were positive: HBsAg (+), 43 (7.6%), isolated anti-HBc (+), 57 (10%), isolated anti-HBs (+), 19 (3.3%), anti-HBc (+)/anti-HBs (+), 90 (15.8%). HBV vaccine indication was performed in 416 patients (73.2%) who either had negative HBV markers or isolated anti-HBc (+). It was more frequently performed in women (82.3% versus 70.3%, P = .005), albeit with no differences according to age or etiology. There were only 8.2% (44/538) IgG-anti-HAV-negative, an indication for vaccination against HAV, which was more frequent affecting patients who were younger [≤ 45 years (27.6%), 46-55 (7.2%), >55 (2.6%); P < .0001)]; nondiabetic (9.5% versus 2.8%, P = .023); nonalcoholic (11.4% versus 6.6%, P = .056); and displayed negative HBV markers (10.2% versus 4.6%, P = .023). Only three patients with IgG-anti- HAV (-) were over 60 years. In conclusion, there is a frequent indication for HBV vaccination among cirrhotic and especially HAV vaccine for under 45 year old patients undergoing evaluation for OLT.

摘要

在缺乏免疫力的情况下,建议慢性肝病患者以及接受肝移植评估的患者接种甲型肝炎病毒(HAV)和乙型肝炎病毒(HBV)疫苗。肝移植后HAV和HBV感染在这种情况下很常见,且与较差的预后相关。本研究的目的是评估肝移植候选肝硬化患者中HBV和HAV疫苗接种的需求,以及与性别、年龄和病因学因素的关联。在568例患者中调查了HBV和HAV血清学标志物,包括乙肝表面抗原(HBsAg)、乙肝核心抗体(anti-HBc)、乙肝表面抗体(anti-HBs)、免疫球蛋白G(IgG)抗-HAV,其中75%为男性。总体平均年龄为53.6±8.9岁(范围17 - 69岁),20%为糖尿病患者。病因包括酒精性(68%)、丙型肝炎病毒(35%)或其他原因(10.4%)。Child-Pugh分级为:A级(26%)、B级(44%)和C级(30%)。与359例(63.2%)HBV标志物阴性的患者相比,209例(36.8%)为阳性:HBsAg(+),43例(7.6%);单独anti-HBc(+),57例(10%);单独anti-HBs(+),19例(3.3%);anti-HBc(+)/anti-HBs(+),90例(15.8%)。416例(73.2%)HBV标志物阴性或单独anti-HBc(+)的患者进行了HBV疫苗接种。女性接种更为频繁(82.3%对70.3%,P = 0.005),尽管按年龄或病因无差异。仅有8.2%(44/538)的IgG抗-HAV阴性,提示需接种HAV疫苗,更常见于年龄较小的患者[≤45岁(27.6%)、46 - 55岁(7.2%)、>55岁(2.6%);P < 0.0001];非糖尿病患者(9.5%对2.8%,P = 0.023);非酒精性患者(11.4%对6.6%,P = 0.056);以及HBV标志物阴性的患者(10.2%对4.6%,P = 0.023)。仅有3例IgG抗-HAV(-)患者年龄超过60岁。总之,肝硬化患者中HBV疫苗接种需求频繁,尤其是45岁以下接受肝移植评估的患者有HAV疫苗接种需求。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验